Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,786 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Platinol Clear all

Conditions: Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
Interventions: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed; Drug
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more

Conditions: Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Cisplatin, Elimusertib, Gemcitabine Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Sacramento, California • Bethesda, Maryland • New York, New York + 3 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, docetaxel, fluorouracil, radiation therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 94
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 61 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: cisplatin, gemcitabine hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 30
States / cities: Los Gatos, California • Tampa, Florida • Chicago, Illinois + 23 more

Conditions: Non-small Cell Lung Cancer
Interventions: canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more

Conditions: Lip and Oral Cavity Cancer, Head and Neck Cancer, Oropharyngeal Cancer
Interventions: cisplatin, fluorouracil, ONYX-015; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Brain and Central Nervous System Tumors
Interventions: aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Testicular Neoplasms
Interventions: Questionnaire; Behavioral
Lead sponsor: Lawrence Einhorn; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Head and Neck Cancer
Interventions: Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab, LymphDetect assay, Surgery +/- neoadjuvant pembrolizumab; Drug · Radiation · Diagnostic Test + 1 more
Lead sponsor: Kevin Contrera; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: G17DT Immunogen, cisplatin, fluorouracil; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer
Interventions: bevacizumab, cisplatin, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Interventions: CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more

Conditions: Pancreatic Cancer, Biliary Cancer
Interventions: Gemcitabine, 5-FU, Cisplatin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Lung Cancer
Interventions: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant, Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: TG4010, placebo; Biological · Drug
Lead sponsor: Transgene; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Scottsdale, Arizona • Topeka, Kansas • Louisville, Kentucky + 9 more

Conditions: Solid Tumor
Interventions: Cetuximab, Cisplatin, 5 - Fluorouracil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Fairway, Kansas • Reno, Nevada + 2 more

Conditions: Cervical Cancer
Interventions: cisplatin, fluorouracil, brachytherapy, radiation therapy; Drug · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: LY900003; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 20
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • Los Angeles, California + 17 more

Conditions: Lung Cancer
Interventions: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 13
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 10 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions: Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Pemetrexed; Drug · Biological · Radiation
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Carboplatin, Cisplatin, Gemcitabine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Louisville, Kentucky

Search by objective public record fields.

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

The Platinum Study Comparison Group

Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

Study in Advanced Solid Tumors

Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma